A recently added report by TMR Research, titled, “U.S. Clinical Oncology Next Generation Sequencing (NGS) Market – Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016–2024,” examines every facet of the market to assess its size, competitive dynamics, and growth prospects.
The report finds that the primary end-users in the U.S. market for clinical oncology next generation sequencing are pharmaceutical and biotech entities, academic research institutes, clinical research, and hospitals and clinics. Of them, academic research institutes account for maximum market share because of rising knowledge about the benefits associated with the implementation of second-generation sequencing in academic and university-based research projects. Depending upon technology, targeted sequencing and re-sequencing contributes the most to the clinical oncology next generation sequencing market in the U.S.
Request a Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=47
By dint of being hassle-free to implement, the use of whole genome sequencing (WGS) technology to compare tumor tissue to normal tissue is expected to witness a steep rise during the forecast period. Researchers also state that WSG will bring about personalized treatment plan.
At the forefront of driving the U.S. clinical oncology next generation sequencing (NGS) market is the rising instances of cancer. Considered a disruptive technology, next generation sequencing helps in uncovering rare forms of cancer mutations, uncovering familial cancer mutation carriers, and in providing molecular rationale for the exact targeted therapy. On account of this, its market holds a lot of potential. With continued enhancement of new sequencing technology, for example, next-generation sequencing (NGS) is being increasingly used in cancer genomics research.
Other factors underpinning the U.S. clinical oncology next generation sequencing (NSG) market has been government initiatives in the field of research and development in oncology. Loans and grants by the U.S. government and other funding bodies to lower the gap between genomic sequence analysis platforms development and their use in oncology research is also stoking growth in the market.
Request for TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=47
Posing a roadblock in the next generation sequencing is the inordinate time taken to unearth insights from the copious amount of data generated after the genome is sequenced. While it aids in accurately studying many genes simultaneously that may be relevant to the patient’s tumor by using only a small amount of tissue at a reasonable cost, it also offers opportunities to commercial service providers to come up with proper solutions in reduced time.
To present a competitive analysis of the U.S. market for clinical oncology next generation sequencing, the report profiles companies such as Roche, llumina Inc., Oxford Nanopore Technologies Ltd, Pacific Bioscience, Agilent Technologies, GATC Biotech Ag, Macrogen Inc., Foundation Medicine, Life technologies Corp, Exosome Diagnostics, CLC Bio, Paradigm, Partek, Inc, GnuBIO, and Caris Life Sciences.
Read Complete Report @ https://www.tmrresearch.com/us-clinical-oncology-next-generation-sequencing-market
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.
Head – Internet Marketing